1. |
Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al. Landscape of transcription in human cells. Nature 2012;489:101-8.
|
2. |
Lee JT. Epigenetic regulation by long noncoding RNAs. Science 2012;338:1435-9.
|
3. |
Zhu S, Li W, Liu J, Chen CH, Liao Q, Xu P, et al. Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. Nat Biotechnol 2016;34:1279-86.
|
4. |
Kambara H, Niazi F, Kostadinova L, Moonka DK, Siegel CT, Post AB, et al. Negative regulation of the interferon response by an interferon-induced long non-coding RNA. Nucleic Acids Res 2014;42:10668-80.
|
5. |
Li Z, Shen J, Chan MT, Wu WK. TUG 1: A pivotal oncogenic long non-coding RNA of human cancers. Cell Prolif 2016;49:471-5.
|
6. |
Jiang X, Ma N, Wang D, Li F, He R, Li D, et al. Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma. Oncotarget 2015;6:3178-94.
|
7. |
Vance KW, Sansom SN, Lee S, Chalei V, Kong L, Cooper SE, et al. The long non-coding RNA Paupar regulates the expression of both local and distal genes. EMBO J 2014;33:296-311.
|
8. |
Huang B, Song JH, Cheng Y, Abraham JM, Ibrahim S, Sun Z, et al. Long non-coding antisense RNA KRT7-AS is activated in gastric cancers and supports cancer cell progression by increasing KRT7 expression. Oncogene 2016;35:4927-36.
|
9. |
Ambros V. microRNAs: Tiny regulators with great potential. Cell 2001;107:823-6.
|
10. |
Zhao Y, Srivastava D. A developmental view of microRNA function. Trends Biochem Sci 2007;32:189-97.
|
11. |
Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer 2015;15:321-33.
|
12. |
Wang F, Fan M, Zhou X, Yu Y, Cai Y, Wu H, et al. A positive feedback loop between TAZ and miR-942-3p modulates proliferation, angiogenesis, epithelial-mesenchymal transition process, glycometabolism and ROS homeostasis in human bladder cancer. J Exp Clin Cancer Res 2021;40:44.
|
13. |
Ou R, Mo L, Tang H, Leng S, Zhu H, Zhao L, et al. circRNA-AKT1 sequesters miR-942-5p to upregulate AKT1 and promote cervical cancer progression. Mol Ther Nucleic Acids 2020;20:308-22.
|
14. |
Guerra Martins dos Santos Assunção JA. Evolutionary Analysis of Animal microRNAs (Doctoral Dissertation, University of Cambridge); 2013.
|
15. |
Zhang J, Zhang Z, Sun J, Ma Q, Zhao W, Chen X, et al. MiR-942 regulates the function of breast cancer cell by targeting FOXA2. Biosci Rep 2019;39:BSR20192298.
|
16. |
Li Z, Zheng J, Lin W, Weng J, Hong W, Zou J, et al. Circular RNA hsa_circ_0001785 inhibits the proliferation, migration and invasion of breast cancer cells in vitro and in vivo by sponging miR-942 to upregulate SOCS3. Cell Cycle 2020;19:2811-25.
|
17. |
Zhang Y, Zhang J, Mao L, Li X. Long noncoding RNA HCG11 inhibited growth and invasion in cervical cancer by sponging miR-942-5p and targeting GFI1. Cancer Med 2020;9:7062-71.
|
18. |
Shan Z, An N, Qin J, Yang J, Sun H, Yang W. Long non-coding RNA Linc00675 suppresses cell proliferation and metastasis in colorectal cancer via acting on miR-942 and Wnt/β-catenin signaling. Biomed Pharmacother 2018;101:769-76.
|
19. |
Fasihi A, Soltani BM, Ranjbaran ZS, Bahonar S, Norouzi R, Nasiri S. Hsa-miR-942 fingerprint in colorectal cancer through Wnt signaling pathway. Gene 2019;712:143958.
|
20. |
Li S, Yan G, Liu W, Li C, Wang X. Circ0106714 inhibits tumorigenesis of colorectal cancer by sponging miR-942-5p and releasing DLG2 via Hippo-YAP signaling. Mol Carcinog 2020;59:1323-42.
|
21. |
Yu C, Li D, Yan Q, Wang Y, Yang X, Zhang S, et al. Circ_0005927 inhibits the progression of colorectal cancer by regulating miR-942-5p/BATF2 axis. Cancer Manag Res 2021;13:2295-306.
|
22. |
Ge C, Wu S, Wang W, Liu Z, Zhang J, Wang Z, et al. miR-942 promotes cancer stem cell-like traits in esophageal squamous cell carcinoma through activation of Wnt/β-catenin signalling pathway. Oncotarget 2015;6:10964.
|
23. |
Lu J, Wang YH, Huang XY, Xie JW, Wang JB, Lin JX, et al. circ-CEP85L suppresses the proliferation and invasion of gastric cancer by regulating NFKBIA expression via miR-942-5p. J Cell Physiol 2020;235:6287-99.
|
24. |
Zhang Q, Zhu B, Qian J, Wang K, Zhou J. miR-942 promotes proliferation and metastasis of hepatocellular carcinoma cells by inhibiting RRM2B. Onco Targets Ther 2019;12:8367-78.
|
25. |
Xu CY, Dong JF, Chen ZQ, Ding GS, Fu ZR. MiR-942-3p promotes the proliferation and invasion of hepatocellular carcinoma cells by targeting MBL2. Cancer Control 2019;26:1073274819846593.
|
26. |
Xu Q, Zhou L, Yang G, Meng F, Wan Y, Wang L, et al. Overexpression of circ_0001445 decelerates hepatocellular carcinoma progression by regulating miR-942-5p/ALX4 axis. Biotechnol Lett 2020;42:2735-47.
|
27. |
Lu L, Li S, Zhang Y, Luo Z, Chen Y, Ma J, et al. GFI1-mediated upregulation of LINC00675 as a ceRNA restrains hepatocellular carcinoma metastasis by sponging miR-942-5p. Front Oncol 2020;10:607593.
|
28. |
Yan Q, Shen C, Qin J, Li W, Hu M, Lu H, et al. HIV-1 Vpr inhibits Kaposi's sarcoma-associated herpesvirus lytic replication by inducing microrna miR-942-5p and activating NF-κB signaling. J Virol 2016;90:8739-53.
|
29. |
Zhang W, Mao K, Liu S, Xu Y, Ren J. miR-942-5p promotes the proliferation and invasion of human melanoma cells by targeting DKK3. J Recept Signal Transduct Res 2021;41:180-7.
|
30. |
Yang F, Shao C, Wei K, Jing X, Qin Z, Shi Y, et al. miR-942 promotes tumor migration, invasion, and angiogenesis by regulating EMT via BARX2 in non-small-cell lung cancer. J Cell Physiol 2019;234:23596-607.
|
31. |
Wang Q, Wu J, Huang H, Jiang Y, Huang Y, Fang H, et al. lncRNA LIFR-AS1 suppresses invasion and metastasis of non-small cell lung cancer via the miR-942-5p/ZNF471 axis. Cancer Cell Int 2020;20:180.
|
32. |
Zhou C, Chen Z, Zhao L, Zhao W, Zhu Y, Liu J, et al. A novel circulating miRNA-based signature for the early diagnosis and prognosis prediction of non-small-cell lung cancer. J Clin Lab Anal 2020;34:e23505.
|
33. |
Wang J, Jiang C, Li N, Wang F, Xu Y, Shen Z, et al. The circEPSTI1/mir-942-5p/LTBP2 axis regulates the progression of OSCC in the background of OSF via EMT and the PI3K/Akt/mTOR pathway. Cell Death Dis 2020;11:682.
|
34. |
Sun D, Zhu D. Circular RNA hsa_circ_0001649 suppresses the growth of osteosarcoma cells via sponging multiple miRNAs. Cell Cycle 2020;19:2631-43.
|
35. |
Du Z, Wang L, Xia Y. Circ_0015756 promotes the progression of ovarian cancer by regulating miR-942-5p/CUL4B pathway. Cancer Cell Int 2020;20:572.
|
36. |
Xie J, Wang S, Li G, Zhao X, Jiang F, Liu J, et al. circEPSTI1 regulates ovarian cancer progression via decoying miR-942. J Cell Mol Med 2019;23:3597-602.
|
37. |
Wong CH, Lou UK, Li Y, Chan SL, Tong JH, To KF, et al. CircFOXK2 promotes growth and metastasis of pancreatic ductal adenocarcinoma by complexing with RNA-binding proteins and sponging MiR-942. Cancer Res 2020;80:2138-49.
|
38. |
Prior C, Perez-Gracia JL, Garcia-Donas J, Rodriguez-Antona C, Guruceaga E, Esteban E, et al. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One 2014;9:e86263.
|
39. |
Chen Y, He J, Su C, Wang H, Chen Y, Guo W, et al. LINC00461 affects the survival of patients with renal cell carcinoma by acting as a competing endogenous RNA for microRNA942. Oncol Rep 2019;42:1924-34.
|
40. |
Luo N, Gao HM, Wang YQ, Li HJ, Li Y. MiR-942-5p alleviates septic acute kidney injury by targeting FOXO3. Eur Rev Med Pharmacol Sci 2020;24:6237-44.
|
41. |
McDonald AC, Vira M, Walter V, Shen J, Raman JD, Sanda MG, et al. Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy. Prostate 2019;79:961-8.
|
42. |
Li Z, Zheng J, Xia Q, He X, Bao J, Chen Z, et al. Identification of specific long non-coding ribonucleic acid signatures and regulatory networks in prostate cancer in fine-needle aspiration biopsies. Front Genet 2020;11:62.
|
43. |
Wu J, Wang J. HMGN5 expression in bladder cancer tissue and its role on prognosis. Eur Rev Med Pharmacol Sci 2018;22:970-5.
|
44. |
Chamie K, Litwin MS, Bassett JC, Daskivich TJ, Lai J, Hanley JM, et al. Recurrence of high-risk bladder cancer: A population-based analysis. Cancer 2013;119:3219-27.
|
45. |
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
|
46. |
Liu W, Schaffer L, Herrs N, Chollet C, Taylor S. Improved sleep after Qigong exercise in breast cancer survivors: A pilot study. Asia Pac J Oncol Nurs 2015;2:232-9. [Full text]
|
47. |
Kam J, Kam J, Mann GB, Phillips C, Wentworth JM, King J, et al. Solitary pituitary metastasis from HER2-positive breast cancer. Asia Pac J Clin Oncol 2017;13:e181-4.
|
48. |
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
|
49. |
Prabhu M, Eckert LO. Development of World Health Organization (WHO) recommendations for appropriate clinical trial endpoints for next-generation Human Papillomavirus (HPV) vaccines. Papillomavirus Res 2016;2:185-9.
|
50. |
Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008;100:513-7.
|
51. |
Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, Goodman RH, et al. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc Natl Acad Sci U S A 2005;102:16426-31.
|
52. |
Blum HE. Hepatocellular carcinoma: Therapy and prevention. World J Gastroenterol 2005;11:7391-400.
|
53. |
Sostres C, Gargallo CJ, Lanas A. Aspirin, cyclooxygenase inhibition and colorectal cancer. World J Gastrointest Pharmacol Ther 2014;5:40-9.
|
54. |
Zhou L, Chen Q, Wu J, Yang J, Yin H, Tian J, et al. miR-942-5p inhibits proliferation, metastasis, and epithelial-mesenchymal transition in colorectal cancer by targeting CCBE1. Biomed Res Int 2021;2021:9951405.
|
55. |
Parkin DM, Bray F. Evaluation of data quality in the cancer registry: Principles and methods Part II. Completeness. Eur J Cancer 2009;45:756-64.
|
56. |
Sitarz R, Skierucha M, Mielko J, Offerhaus GJ, Maciejewski R, Polkowski WP. Gastric cancer: Epidemiology, prevention, classification, and treatment. Cancer Manag Res 2018;10:239-48.
|
57. |
Invernizzi F, Viganò M, Grossi G, Lampertico P. The prognosis and management of inactive HBV carriers. Liver Int 2016;36 Suppl 1:100-4.
|
58. |
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301-14.
|
59. |
Lee JS. The mutational landscape of hepatocellular carcinoma. Clin Mol Hepatol 2015;21:220-9.
|
60. |
Liu N, Zuo C, Wang X, Chen T, Yang D, Wang J, et al. miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT. Oncotarget 2014;5:4959-71.
|
61. |
Yang D, Meng X, Xue B, Liu N, Wang X, Zhu H. MiR-942 mediates hepatitis C virus-induced apoptosis via regulation of ISG12a. PLoS One 2014;9:e94501.
|
62. |
Tao L, Xue D, Shen D, Ma W, Zhang J, Wang X, et al. MicroRNA-942 mediates hepatic stellate cell activation by regulating BAMBI expression in human liver fibrosis. Arch Toxicol 2018;92:2935-46.
|
63. |
Tao L, Wu L, Zhang W, Ma WT, Yang GY, Zhang J, et al. Peroxisome proliferator-activated receptor γ inhibits hepatic stellate cell activation regulated by miR-942 in chronic hepatitis B liver fibrosis. Life Sci 2020;253:117572.
|
64. |
Stănescu L, Foarfă C, Georgescu AC, Georgescu I. Kaposi's sarcoma associated with AIDS. Rom J Morphol Embryol 2007;48:181-7.
|
65. |
Ganem D. KSHV and the pathogenesis of Kaposi sarcoma: Listening to human biology and medicine. J Clin Invest 2010;120:939-49.
|
66. |
Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010;10:707-19.
|
67. |
Gates AE, Kaplan LD. AIDS malignancies in the era of highly active antiretroviral therapy. Oncology (Williston Park) 2002;16:657-65.
|
68. |
Fan C, Moews PC, Walsh CT, Knox JR. Vancomycin resistance: Structure of D-alanine: D-alanine ligase at 2.3 A resolution. Science 1994;266:439-43.
|
69. |
Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332:1186-91.
|
70. |
Zuur AF, Ieno EN, Walker NJ, Saveliev AA, Smith GM. Ebooks Corporation. Mixed effects models and extensions in ecology with R [Internet]. In: Statistics for Biology and Health. New York: Springer; 2009.
|
71. |
Carr S, Smith C, Wernberg J. Epidemiology and risk factors of melanoma. Surg Clin North Am 2020;100:1-12.
|
72. |
Owens B. Melanoma. Nature 2014;515:S109.
|
73. |
Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: Epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo 2014;28:1005-11.
|
74. |
Varrone F, Caputo E. The miRNAs role in melanoma and in its resistance to therapy. Int J Mol Sci 2020;21:878.
|
75. |
O'Neill CH, Scoggins CR. Melanoma. J Surg Oncol 2019;120:873-81.
|
76. |
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
|
77. |
van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet 2011;378:1741-55.
|
78. |
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403.
|
79. |
Yu JS, Chen YT, Chiang WF, Hsiao YC, Chu LJ, See LC, et al. Saliva protein biomarkers to detect oral squamous cell carcinoma in a high-risk population in Taiwan. Proc Natl Acad Sci U S A 2016;113:11549-54.
|
80. |
Giovannacci I, Vescovi P, Manfredi M, Meleti M. Non-invasive visual tools for diagnosis of oral cancer and dysplasia: A systematic review. Med Oral Patol Oral Cir Bucal 2016;21:e305-15.
|
81. |
Maleki D, Ghojazadeh M, Mahmoudi SS, Mahmoudi SM, Pournaghi-Azar F, Torab A, et al. Epidemiology of oral cancer in Iran: A systematic review. Asian Pac J Cancer Prev 2015;16:5427-32.
|
82. |
Liu D, Zhao X, Zeng X, Dan H, Chen Q. Non-invasive techniques for detection and diagnosis of oral potentially malignant disorders. Tohoku J Exp Med 2016;238:165-77.
|
83. |
Rivera C. Essentials of oral cancer. Int J Clin Exp Pathol 2015;8:11884-94.
|
84. |
Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009;115:1531-43.
|
85. |
Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q, et al. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One 2012;7:e33778.
|
86. |
Amankwah EK, Conley AP, Reed DR. Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol 2013;5:147-62.
|
87. |
Bacci G, Briccoli A, Rocca M, Ferrari S, Donati D, Longhi A, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: Recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 2003;14:1126-34.
|
88. |
Rainusso N, Wang LL, Yustein JT. The adolescent and young adult with cancer: State of the art – Bone tumors. Curr Oncol Rep 2013;15:296-307.
|
89. |
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet 2014;384:1376-88.
|
90. |
Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers 2016;2:1-22.
|
91. |
Tew WP, Muss HB, Kimmick GG, Von Gruenigen VE, Lichtman SM. Breast and ovarian cancer in the older woman. J Clin Oncol 2014;32:2553-61.
|
92. |
Longuespée R, Boyon C, Desmons A, Vinatier D, Leblanc E, Farré I, et al. Ovarian cancer molecular pathology. Cancer Metastasis Rev 2012;31:713-32.
|
93. |
Kleeff J, Costello E, Jackson R, Halloran C, Greenhalf W, Ghaneh P, et al. The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. Br J Cancer 2016;115:887-94.
|
94. |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30.
|
95. |
Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10.
|
96. |
Simianu VV, Zyromski NJ, Nakeeb A, Lillemoe KD. Pancreatic cancer: Progress made. Acta Oncol 2010;49:407-17.
|
97. |
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
|
98. |
Rathmell WK, Godley PA. Recent updates in renal cell carcinoma. Curr Opin Oncol 2010;22:250-6.
|
99. |
Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30:843-52.
|
100. |
Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, et al. The role of sarcosine metabolism in prostate cancer progression. Neoplasia 2013;15:491-501.
|
101. |
Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: Connecting the dots. Mol Cancer 2006;5:17.
|
102. |
Sadeghi RN, Karami-Tehrani F, Salami S. Targeting prostate cancer cell metabolism: Impact of hexokinase and CPT-1 enzymes. Tumour Biol 2015;36:2893-905.
|
103. |
Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, et al. Targeting cancer cell metabolism: The combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010;70:2465-75.
|